Home > Healthcare > Biotechnology > Biopharma > Antibody Therapy Market

Antibody Therapy Market Trends

Report ID: GMI5195
Published Date: Dec 2023
Report Format: PDF

Download Free Sample

Antibody Therapy Market Trends

The government and key market players have significantly increased R&D expenditure due to the high demand for antibody therapy in the market. Governmental support for the launch of novel treatment is expected to contribute to strong market growth. In September 2021, Amgen received FDA approval for its Repatha (evolocumab) for the treatment of heterozygous familial hypercholesterolemia (HeFH) patients aged 10 years and older. This approval will benefit the patients suffering from HeFH.
Moreover, growing regulatory approvals and the introduction of new drugs further contribute to this positive trend. For instance, between April and June 2023, approvals included antibody-drug conjugates for diverse cancers, bispecific T-cell engagers targeting B-cell malignancies, with other applications. As the global cancer risk escalates, there is an increased demand for clinically secure treatments, favouring antibodies.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global antibody therapy industry size accounted for USD 214.7 billion in 2022 and is expected to reach USD 638.2 billion by end of 2032, favored by the approval of new therapies and drugs for the treatment of diseases.

The hospitals segment held the major market share of 47.6% in 2022 and will continue to grow owing to its role as a primary healthcare provider for severe and chronic diseases. Hospitals have specialized infrastructure, skilled personnel, and advanced technology required for administering and monitoring antibody therapies.

North America antibody therapy market is expected surpass USD 284 billion by 2032, owing to the robust regulatory framework as well as rising investment in novel antibody therapy development by key players.

F. Hoffmann-La Roche Ltd., AbbVie, Inc., Amgen Inc., Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Seagen, Merck & Co., Inc., Regeneron Pharmaceuticals Inc., and Novartis AG among others.